3Yarranto H, Cohen H, Pavord SP, et al. Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura [J]. Br J Haematol. 2003 Jun; 121 (5): 778-85.
4Nabhan C, Kwaan HC. Current Concepts in the diognosis and management of thrombocic thrombocytopenic purpura [J]. Hematol Dncol Clin North Am. 2003 Feb; 17 (1): 177-99.
5Pinanda JE, Chestrman CN, HoggPJ. A persptctive on the measurement of ADAMTS13 in thrombotic thrombocytopaenic purpura [J]. Eur J Haematol. 2003Apr: 70 (4): 257-62.
6Gerritsen HE, Turecek PL, Schwaraz HP, et al. Assay of von willebrand factor (vWF) - Cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP) [J]. Thromb Haemost. 1999, 82:1386- 1389.
8Schneppenheim R,Budde U,Oyen F,et al.von Willebrand factor cleaving protease and ADAMTS 13 mutation in childhood TTP.Blood,2003,101(5):1845-1853.
9Vesely SK,George JN,Lammle B,et al.ADAMTS 13 activty in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome:relation to presenting fentures and clinical outcomes in a prospective cohort of 142 patients,Blood,2003,102(1):60-68.
10Savasan S,Lee S-K,Ginsburg D,et al.ADAMTS 13 gene mutation in congenital thrombotic thrombocytopenic purpura with previously reported normal VWF cleaving protease activity.Blood,2003,101(11):4449-1151.
